Novo Nordisk ends two heart-failure studies early for lack of efficacy
Novo Nordisk said it is ending two heart-failure studies early after concluding it was unlikely ziltivekimab would achieve the expected outcome.
Novo Nordisk said it is ending two heart-failure studies early after concluding they were unlikely to deliver the expected outcome. The two trials were testing the company’s experimental cardiovascular drug ziltivekimab to assess whether it could be used to treat patients with hear…